This area of research is showing promise as it has recently been reported in both in vitro and xenograft models that anti-AR therapy inhibits the growth of Her2+ve breast cancer to an equivalent level as the anti-Her2+ve therapy trastuzumab and therefore could be used as a second line therapy in this setting (96). Here, ERBB2 is linked to breast carcinoma.